Lilly to enter radiopharmaceutical drug field with $1.4B …

Eli Lilly inks another radiopharma deal, gaining option to buy startupLilly partners with Aktis, deepening radiopharma investment

CouponFollow Extension

$1
OFF

Lilly To Enter Radiopharmaceutical Drug Field With $1.4B …

4 weeks from now

Eli Lilly inks another radiopharma deal, gaining option to buy startupLilly partners with Aktis, deepening radiopharma investment

biopharmadive.com

$1
OFF

Eli Lilly Jumps Into Radiopharmaceuticals Via $1.4B Point …

4 weeks from now

Oct 3, 2023 · Eli Lilly’s scope in cancer is expanding to radiopharmaceuticals with the $1.4 billion acquisition of Point Biopharma Global, a company in late-stage clinical development with two …

medcitynews.com

$140
OFF

Eli Lilly Inks Another Radiopharma Deal, Gaining Option To Buy Startup

4 weeks from now

Jul 1, 2024 · Lilly will pay Radionetics $140 million upfront for the option rights under the deal, which the companies announced Monday. Radionetics will continue to build its …

biopharmadive.com

$1
OFF

Lilly Enters Radiopharma Space With $1.4B Buyout Of Point

4 weeks from now

Oct 3, 2023 · Eli Lilly and Co. agreed to acquire Point Biopharma Global Inc. for $12.50 per share in cash, or about $1.4 billion, in a deal that would bring the pharma company a pipeline of …

bioworld.com

$1
OFF

Eli Lilly Forays Into Radiopharmaceuticals With $1.4B POINT Buy

4 weeks from now

Oct 3, 2023 · Eli Lilly will acquire POINT Biopharma as the drugmaker looks to definitively expand its oncology capabilities into next-gen radioligand therapies. Per the agreement, Lilly will …

pharmamanufacturing.com

$140
OFF

Lilly Signs $140M Radiopharma Partnership With Radionectics

4 weeks from now

Jul 1, 2024 · The agreement also gives Lilly the option to buy the Crinetics spinout for a cool $1 billion at the end of an exercise period. Lilly dived into the nascent radiopharma space by …

fiercebiotech.com

$1
OFF

Lilly Looks To Take POINT On Emerging Cancer ... - Scrip

4 weeks from now

Oct 3, 2023 · Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a …

citeline.com

$1
OFF

Lilly Enters Radiopharma Space With $1.4B Buyout Of Point

4 weeks from now

Oct 3, 2023 · Indianapolis-based Eli Lilly and Co. agreed to acquire Point Biopharma Global Inc. for $12.50 per share in cash, or about $1.4 billion, in a deal that would bring the pharma …

bioworld.com

$1
OFF

How Novartis Is Disrupting Lilly's $1.4B Radiotherapy Plan - Fierce …

4 weeks from now

Dec 5, 2023 · On Oct. 3, Eli Lilly unveiled a $1.4 billion agreement to acquire cross-town radiopharmaceutical company Point Biopharma Global to beef up its oncology capabilities. …

fiercebiotech.com

$140
OFF

Lilly Inks Radiopharma Deal With Radionetics, With Rights To Buy The ...

4 weeks from now

Jul 1, 2024 · Eli Lilly is further delving into the radiopharmaceutical field with a $140 million upfront deal with Radionetics Oncology. The strategic pact with the San Diego biotech could turn into …

sdbn.org

$60
OFF

Lilly Pays Aktis $60M To Further Dial Into Radiopharma Signal

4 weeks from now

May 21, 2024 · Eli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to work on therapeutic and diagnostic products against multiple targets. Lilly …

fiercebiotech.com

FAQs about Lilly to enter radiopharmaceutical drug field with $1.4B … Coupon?

Will Eli Lilly buy point Biopharma?

Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1.4 billion. Per acquisition terms, Lilly will pay $12.50 per Point share, a premium of about 87% to what the biotechnology company’s stock closed at Monday. ...

Will Eli Lilly buy radionetics oncology?

Scott Olson via Getty Images Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option to later acquire the San Diego biotechnology company for $1 billion. Lilly will pay Radionetics $140 million upfront for the option rights under the deal, which the companies announced Monday. ...

Why is Lilly partnering with a pharma company to develop radiopharma?

Recent improvements in manufacturing and supplying the complex treatments have boosted investment in the field, drawing interest from large pharma companies like Lilly as well as new drug startups. The Point deal appears to be part of a broader plan by Lilly to build a presence in radiopharma drug development. ...

Will Lilly buy radionetics?

Radionetics will continue to build its radiopharmaceutical drug pipeline through an “exercise period,” after which Lilly can choose whether to acquire the company. Radionetics is developing small molecule radiopharmaceuticals that can target G protein-coupled receptors, a ubiquitous family of proteins that present many attractive disease targets. ...

Will Eli Lilly buy a treatment for metastatic prostate cancer?

One of the experimental drugs Eli Lilly will acquire is a treatment for metastatic prostate cancer. Dr_Microbe via Getty Images Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1.4 billion. ...

Is Lilly behind the curve in radiopharmaceuticals?

Lilly is slightly behind the curve, striking the deal well after Novartis dove in headfirst to the radiopharmaceuticals space. While Lilly has previously put money behind radiopharmaceutical companies—like supporting Mariana Oncology’s $175 million series B last month—Novartis has made radiopharmaceuticals a pillar of its cancer strategy. ...